Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Mirvetuximab Soravtansine and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03552471Phase 1Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mirvetuximab soravtansine and rucaparib in endometrial cancer (EC), ovarian cancer, fallopian tube cancer (PFTC) and 1 more, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Recommended Phase II Dose. Started Jul 2018; status: completed.
02
Drugs
mirvetuximab soravtansinerucaparib
03
Conditions
endometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03552471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552471.